These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 31105589)
1. Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and Injury. Pöyhönen S; Er S; Domanskyi A; Airavaara M Front Physiol; 2019; 10():486. PubMed ID: 31105589 [TBL] [Abstract][Full Text] [Related]
2. Astrocyte-derived GDNF is a potent inhibitor of microglial activation. Rocha SM; Cristovão AC; Campos FL; Fonseca CP; Baltazar G Neurobiol Dis; 2012 Sep; 47(3):407-15. PubMed ID: 22579772 [TBL] [Abstract][Full Text] [Related]
3. Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats. Renko JM; Bäck S; Voutilainen MH; Piepponen TP; Reenilä I; Saarma M; Tuominen RK Mol Neurobiol; 2018 Aug; 55(8):6755-6768. PubMed ID: 29349573 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of the endoplasmic reticulum located and secreted CDNF/MANF family of neurotrophic factors in Parkinson's disease. Voutilainen MH; Arumäe U; Airavaara M; Saarma M FEBS Lett; 2015 Dec; 589(24 Pt A):3739-48. PubMed ID: 26450777 [TBL] [Abstract][Full Text] [Related]
5. Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism. Lindholm P; Saarma M Mol Psychiatry; 2022 Mar; 27(3):1310-1321. PubMed ID: 34907395 [TBL] [Abstract][Full Text] [Related]
6. CDNF Protein Therapy in Parkinson's Disease. Huttunen HJ; Saarma M Cell Transplant; 2019 Apr; 28(4):349-366. PubMed ID: 30947516 [TBL] [Abstract][Full Text] [Related]
7. Neurotrophic Factors in Parkinson's Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain. Bondarenko O; Saarma M Front Cell Neurosci; 2021; 15():682597. PubMed ID: 34149364 [TBL] [Abstract][Full Text] [Related]
8. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action. Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK eNeuro; 2017; 4(1):. PubMed ID: 28303260 [TBL] [Abstract][Full Text] [Related]
9. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Voutilainen MH; Bäck S; Peränen J; Lindholm P; Raasmaja A; Männistö PT; Saarma M; Tuominen RK Exp Neurol; 2011 Mar; 228(1):99-108. PubMed ID: 21185834 [TBL] [Abstract][Full Text] [Related]
10. Neurotrophic factors hold promise for the future of Parkinson's disease treatment: is there a light at the end of the tunnel? Nasrolahi A; Mahmoudi J; Akbarzadeh A; Karimipour M; Sadigh-Eteghad S; Salehi R; Farhoudi M Rev Neurosci; 2018 Jul; 29(5):475-489. PubMed ID: 29305570 [TBL] [Abstract][Full Text] [Related]
11. Pitx3-transfected astrocytes secrete brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor and protect dopamine neurons in mesencephalon cultures. Yang D; Peng C; Li X; Fan X; Li L; Ming M; Chen S; Le W J Neurosci Res; 2008 Nov; 86(15):3393-400. PubMed ID: 18646205 [TBL] [Abstract][Full Text] [Related]
12. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. Petrova P; Raibekas A; Pevsner J; Vigo N; Anafi M; Moore MK; Peaire AE; Shridhar V; Smith DI; Kelly J; Durocher Y; Commissiong JW J Mol Neurosci; 2003 Apr; 20(2):173-88. PubMed ID: 12794311 [TBL] [Abstract][Full Text] [Related]